*Refresh the page if the below document does not appear.
Glenmark pharma's drugs are adulterated: claims USFDA
The US drug regulatory body conducted an inspection at Glenmark’s Bardez-based unit in Goa from May 12-20. They identified a number of incompetencies in creating drug formulations, which was mentioned in a warning letter sent to Glenmark’s Chairman and MD Glenn Saldanha.
Drug regulating authorities and pharma firms takes action on fake and substandard drugs
Drug regulators and Pharma companies are stepping up to curb the production and marketing of spurious and substandard drugs in the country. According to ASPA report, the detection of such drugs increased by 47% from 2020 to 2021.
GSK pharma wagers on growing adult vaccine and pediatric immunization market
Pharma major GSK is betting on power brands, innovation in launching products comprising adult vaccines and strong recovery in pediatric immunization to grow exponentially in its crucial emerging market, India.
Researchers successful in finding potent drug to treat autoimmune ITP Blood disorder
According to the results from the ADVANCE IV clinical trial, which was carried out all over the world, patients taking ‘efgartigimod’ , the drug under trial for use to treat chronic primary immune thrombocytopenia (ITP) showed a significantly greater improvement in platelet counts as compared to those taking placebo.
Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement
Kite Pharma, a company acquired by Gilead, and Daiichi Sankyo Co., Ltd. have jointly announced the revision of their 2017 partnership agreement, which gave Daiichi exclusive rights to develop, manufacture, and market Yescarta (axicabtagene ciloleucel) in Japan.
Bristol Myers supports Breyanzi's case related to earlier Lymphoma amidst rivalry with Gilead
An year ago when Bristol Myers Squibb presented important data for Breyanzi in second-line large B-cell lymphoma (LBCL), a significant weak point was a short follow-up time in the study. Now, the New York pharma is cranking up its CAR-T rivalry against Gilead Sciences with updated results.
TherapeuticsMD lays off all of its workforce after licensing products out for $153 million
Earlier this week, TherapeuticsMD licensed
out its products to Mayne Pharma for about
153 million USD. Following this, according
to a notice filed in Florida, the company is
now planning to lay off its entire workforce
of 212 people.
